Back to today’s briefing

Story perspectives

GeneDx Shares Surge 13.2% After FDA AI Approval

1/7/2025

40 2

Summary

Story summary

GeneDx's shares jumped 13.2% to $89.61 following the FDA's new AI guidance for medical devices.
The stock soared nearly 2,700% last year and has increased almost 30-fold in 2024.
GeneDx specializes in whole genome and exome sequencing, targeting rare diseases in children.
The company aims to reduce diagnostic delays by focusing on diseases with available solutions.

1 of 1

Story summary

GeneDx's shares jumped 13.2% to $89.61 following the FDA's new AI guidance for medical devices.
The stock soared nearly 2,700% last year and has increased almost 30-fold in 2024.
GeneDx specializes in whole genome and exome sequencing, targeting rare diseases in children.
The company aims to reduce diagnostic delays by focusing on diseases with available solutions.